



SHUKRA

PHARMACEUTICALS LTD.

22nd August, 2026

To,
The Listing Compliance Department
BSE Limited
P. J. Towers, Dalal Street
Mumbai – 400001
Scrip Code: 524632

To,
The Listing Department
National Stock Exchange of India
Limited
Exchange Plaza, C-1, Block G
Bandra Kurla Complex, Bandra (East)
Mumbai – 400051
Symbol: SHUKRAPHAR

Dear Sir/Madam,

Sub: Outcome of the meeting of the Board of Directors held on Saturday, 22nd August, 2026
Ref: Regulation 30 & 33 of the Securities and Exchange Board of India (Listing Obligation and Disclosure Requirement) Regulation, 2015

Pursuant to Regulation 30 and 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations 2015, the Board of Directors of the Company at their meeting held today i.e. 22nd August, 2026 at the Registered Office of the Company *inter-alia* has, considered and approved the following: -

1. Approval for change of the name of the company in line of proposed new main object of the Company & alteration in Name Clause of MOA, subject to shareholders and relevant regulatory bodies approval and to authorise any director or KMP to file prescribed form in ROC, Ahmedabad; Reservation of proposed name from 'Shukra Pharmaceuticals Limited' to 'Shukra Medtech Limited'.

The details required under Regulation 30 read with Part A of Schedule III of the SEBI (LODR) Regulations, 2015 read with SEBI Circular No. SEBI/HO/CFD/PoD2/CIR/P/0155 dated 11th November, 2024 is given in the enclosed Annexure-I.

2. Recommended the alteration in the main objects of the Company and consequential Alteration in the Main Object Clause of the Memorandum of Association, subject to shareholders' approval through the postal ballot as required under Rule 22(16)(a) of Companies (Management & Administration) Rules, 2014.

The details required under Regulation 30 read with Part A of Schedule III of the SEBI (LODR) Regulations, 2015 read with SEBI Circular No. SEBI/HO/CFD/PoD2/CIR/P/0155 date 11th November 2024 is given in enclosed Annexure II.

CIN : L24231GJ1993PLC019079




3. Approval to draft notice of Postal Ballot to obtain shareholders' approval for the aforesaid relevant agenda items.
4. Appointment of CS Rupal Patel as a Scrutinizer to scrutinize the e-voting process in a fair and transparent manner.
5. Approval of Director's Report for the year ended on March 31, 2026 and adoption of Secretarial Audit Report pursuant to Section 204(l) of the Companies Act, 2013 and rule 9 of the Companies (Appointment & Remuneration Personnel) Rules, 2014 for the year ended on March 31, 2026;
6. Convening the 33rd (Thirty-Third) Annual General Meeting ("AGM") of the shareholders of the Company at 12.00 P.M. (IST), on 25th September, 2026, through Video Conferencing (VC) for seeking their approval and approved the draft Notice of AGM;
7. Register of Members & Share Transfer Books of the Company will remain close from 19th September, 2026 to 25th September, 2026 (both days inclusive) for the purpose of 33rd Annual General Meeting (AGM) of the company;
8. Approval to the Draft of notice of AGM
9. Appointment of Mrs. Rupal Patel, Practicing Company Secretary as Scrutinizer of Remote E-voting as well as voting at the AGM;
10. Reviewed the other businesses of the company


The Board Meeting commenced at 01.30 p.m. and concluded at 2.30 p.m.

You are requested to take the above information on records and disseminate the same on your respective websites.

Thanking you,
Yours faithfully

For Shukra Pharmaceuticals Limited


Ritu Kapoor
Director
DIN: 10334249



CIN : L24231GJ1993PLC019079



ANNEXURE I

DISCLOSURE OF MATERIAL EVENT UNDER REGULATION 30(2) OF SEBI (LISTING OBLIGATION AND DISCLOSURE REQUIREMENTS) REGULATION, 2015- SUMMARY OF AMENDMENTS TO THE MOA & AOA OF THE COMPANY

Pursuant to provisions of Regulation 30(2) of SEBI (Listing Obligation and Disclosure Requirements) Regulation, 2015 read with SEBI Circular No. SEBI/HO/CFD/PoD2/CIR/P/0155 dated 11th November, 2024, the Company hereby discloses the material event as provided in the Schedule III of Listing Regulations:

Board of Directors of the Company has duly considered and approved the proposed change of the Company's name from "Shukra Pharmaceuticals Limited" to "Shukra Medtech Limited" contingent upon the approval of the Central Registration Centre (CRC), Ministry of Corporate Affairs and other relevant authority(ies), if any. This change is also subject to the approval of the members in a General Meeting and the subsequent amendment of the Memorandum of Association and Articles of Association of the Company to reflect the name as approved by respective authorities.

You are requested to take the above cited information on your record.

CIN : L24231GJ1993PLC019079



ANNEXURE II

DISCLOSURE OF MATERIAL EVENT UNDER REGULATION 30(2) OF SEBI (LISTING OBLIGATION AND DISCLOSURE REQUIREMENTS) REGULATION, 2015- SUMMARY OF AMENDMENTS TO THE MOA OF THE COMPANY

Pursuant to provisions of Regulation 30(2) of SEBI (Listing Obligation and Disclosure Requirements) Regulation, 2015 read with SEBI Circular No. SEBI/HO/CFD/PoD2/CIR/P/0155 dated 11th November, 2024, the Company hereby discloses the material event as provided in the Schedule III of Listing Regulations:

The following sub clause (2), (3), (4), (5) and (6) to be appended after sub clause (1) of clause III (A) of the Memorandum of Association of Company:

1. To carry on the business of research, innovation, design, development, engineering, manufacturing assembling fabrication, processing, testing, validation, installation, commissioning, licensing, and commercialization of medical devices, medical equipment, diagnostic systems, surgical instruments, surgical robotic systems, implantable devices, wearable healthcare devices, artificial intelligence-based healthcare technologies, healthcare software, digital health platforms, telemedicine systems, hospital automation solutions, and other healthcare and MedTech products and solutions.
2. To act as manufacturers, buyers, sellers, importers, exporters, distributors, stockists, wholesalers, retailers, agents, representatives, licensors, franchisees, and dealers in all kinds of medical technology products, healthcare devices, diagnostic equipment, robotic surgery systems, AI-driven healthcare solutions, laboratory equipment, hospital consumables, rehabilitation devices, healthcare software, and allied products, in India and abroad.
3. To enter into strategic alliances, collaborations, technical partnerships, joint ventures, licensing arrangements, technology transfer agreements, franchise arrangements, and original Equipment Manufacturer (OEM) agreements with Indian and foreign companies, institutions, research organizations, hospitals, universities, and governments for co-development, manufacturing, marketing, maintenance, and commercialization of healthcare and medical technology products and services.
4. To establish, acquire, develop, construct, operate, maintain, lease, manage, and promote Medical Technology Parks, healthcare industrial clusters, research laboratories, incubation centers, innovation hubs, manufacturing units, clean-room facilities, testing centers, warehouses, and allied infrastructure for the promotion and growth of healthcare technology and medical device industries.
5. To provide installation, commissioning, maintenance, repair, calibration, validation, technical support, consulting, training, certification, educational programs, and skill development services relating to medical devices, robotic surgical systems, healthcare software, digital healthcare technologies, and other MedTech products for hospitals, clinics, healthcare professionals, distributors, institutions, and government agencies.
6. To develop, acquire, license, market, maintain, and operate healthcare software, intelligence artificial systems, machine learning applications, cloud-based healthcare platforms, electronic medical record systems, hospital information systems, remote monitoring systems, cybersecurity solutions for healthcare, and other digital healthcare technologies and services.

CIN : L24231GJ1993PLC019079